How do regulations affect cannabis research for AS? 

The pace of medical cannabis research for ankylosing spondylitis is heavily shaped by legal and regulatory frameworks. While interest in cannabis-based treatment is growing, restrictive cannabis laws in the UK often slow down the ability to conduct clinical trials or expand access to new therapies. 

Regulations dictate which institutions can conduct research, how substances are handled, and who can prescribe approved medications. As a result, much of the emerging data comes from observational studies or research abroad. Access through UK clinics and licensed dispensaries remains limited, which can affect patient participation in trials. 

Research and Regulation Snapshot 

Schedule classification matters 

Cannabis is still classified as a controlled substance, creating hurdles for researchers needing special licences. 

Limited clinical infrastructure 

Only a small number of facilities are authorised to study cannabis in depth, delaying domestic research. 

Prescription constraints 

Prescribers must show that all other treatments have failed before recommending cannabis, limiting data volume. 

Slow policy shifts 

While changes are underway, they haven’t yet opened the door to large-scale AS studies in the UK. 

Visit providers like LeafEase for personal consultations and to stay informed about new developments in research and patient access. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Ankylosing Spondylitis and medical cannabis.